This week's sponsor is Premier Research. | | Placebo Response: A Real Threat to Pain Trials Rising placebo response rates skew analgesia clinical trial data and limit treatment options for suffering patients. Learn how to manage this pain point in analgesia trials with our free eBook. Premier Research. It's what we do. Best. | Today's Rundown 4 years after mega IPO, Circassia set for small-cap exchange Amgen teams with Entera to develop oral biologics Janssen alums' Aro Biotherapeutics takes aim at centyrins with $13M round Ra Pharma files $100M round as Soliris rival clears phase 2 trial GenEdit reels in $8.5M to tackle delivery for gene therapy, gene editing Black Diamond debuts with $20M, mission to drug unexplored oncogenes Featured Story | Tuesday, December 11, 2018 Four years ago, Circassia looked to have ushered in a new era for biotech IPOs on the London Stock Exchange when it raised £200 million ($252 million) to finance development of anti-allergy drugs. Today, Circassia is set to limp away from the main London stock exchange to take up a spot on the AIM submarket, having failed to live up to expectations as a company or as a harbinger of change. |
|
| Top Stories Tuesday, December 11, 2018 Amgen has struck a deal with Entera Bio to develop oral formulations of up to three large molecules. The agreement sees Amgen pay a “modest” upfront fee to access Entera’s technology and commit to up to $270 million in milestones. Tuesday, December 11, 2018 A pair of former Janssen R&D leaders founded Aro Biotherapeutics early this year to develop centyrins—small proteins that could potentially work like antibodies without the accompanying challenges. Now, Aro has raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer. Tuesday, December 11, 2018 Armed with a phase 2 win for its lead drug zilucoplan in rare disease myasthenia gravis, Ra Pharma has pressed the button on a public funding round that it hopes could raise up to $115 million. Tuesday, December 11, 2018 In October last year, a team of UC Berkeley scientists reported a new, nonviral CRISPR-delivery system that might address safety concerns with the gene-editing technology. Now, their company, GenEdit, has picked up $8.5 million in seed funding to develop their nanoparticle system. Tuesday, December 11, 2018 Versant Ventures is unveiling Black Diamond Therapeutics, a biotech developing cancer treatments that target an “undrugged and unexplored” group of oncogenes: allosteric mutant oncogenes. The company is the first to launch out of Ridgeline, Versant’s discovery engine in Basel, Switzerland, and it’s doing so with $20 million from Versant. Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Approval, Manufacturing Quality & Regulation 2018 | Online FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore |